| INSMED INC. DL-,01 |
| USA |
| Gesundheit |
| US4576693075 / A1JJA3 |
| IM8N (Frankfurt) / INSM (NASDAQ) |
| FRA:IM8N, ETR:IM8N, IM8N:GR, NASDAQ:INSM |
| - |
| https://insmed.com/ |
|
Insmed Inc. is a global biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with serious and rare diseases, particularly those affecting the lungs. Its first commercial product, ARIKAYCE (amikacin l..
>Volltext.. |
| 25619.82 Mio. EUR |
| 25048.64 Mio. EUR |
| 516.19 Mio. EUR |
| -832.75 Mio. EUR |
| -1086.79 Mio. EUR |
| -5.45 EUR |
| 643.5 Mio. EUR |
| 434.49 Mio. EUR |
| -795.89 Mio. EUR |
| 3.05 |
| 46.96% |
| -23.16% |
| - |
| - |
| - |
| INSMED |
| 07.05.26 |
|